With great interest I read the recently published work by Schlenk and colleagues that addressed the controversially discussed issue of lowering blood glucose levels in patients suffering from aneurismal subarachnoid hemorrhage [1]. These critically illpatients are at increased risk of developing secondary brain damage whenever blood glucose levels are too high or too low.The authors focused on the initial 12 hours following insulin administration and showed stable blood glucose concentrations with an average of approximately 8 mM. Given a predefined limit of intervention (140 mg/dl = 7.8 mM), the administered insulin dose must therefore have been rather small. Blood glucose appeared stable at least during the presented 14-hour period, which is also in line with our observations avoiding lower blood glucose targets as propagated by van den Berghe and colleagues (4.4–6.1 mM) [2]. The extracellular glucose decreased significantly by 3 hours following insulin infusion. Schlenk and colleagues interpret these changes as an increase in cerebral glucose utilization. This interpretation, however, is difficult to understand since cerebral glucose uptake occurs independently of insulin and the blood glucose levels remained stable.The calculated increased lactate/glucose ratio [3] suggests sustained glycolysis-driven lactate production over time. Whether this is a consequence of insulin treatment (for which specific data are missing), is a consequence of underlying injury with variable degrees of damage, is caused by different starting time points of insulin administration, is overshadowed by different degrees of sedation (awake, deep barbituratecoma, hypothermia), or is overshadowed by varying penetration depths of the microdialysis probes remains unclear. In addition, the exact nutritional regimen also needs to be explained. Addition of these important pieces of information would help one to draw appropriate conclusions.
Author's response
Florian Schlenk and Asita SarrafzadehWe are pleased that our work evokes the interest of the readership. Indeed, avoidance of hypoglycemia is of major importance in brain-lesioned patients, which explains our moderate regimen for glycemic control (target range 80–140 mg/dl) [1].Unexpectedly, 3 hours after insulin onset, the cerebral glucose decreased despite stable blood levels [1]. The underlying mechanisms remain unclear, as physiologic cerebral glucose uptake seems to occur independently of insulin [4]. Yet insulin receptors are widely spread in cerebral tissue, and the injured brain might react differently. The risk of cerebral glucose depletion is stressed by severe metabolic derangements demonstrated during lowered brain glucose in traumatic brain injury and subarachnoid hemorrhage [5,6].Cerebral glucose levels can be influenced by various factors, which cannot all be controlled in a clinical setting. Interindividual differences as quoted by Dr Stover (catheter depth or degree of damage and sedation), however, can hardly explain longitudinal changes over time, and barbiturates or hypothermia were not applied. Nutrition-related effects should be mediated by glucose changes, which were recorded. Ischemia could also widely be excluded [1], and an increase in the lactate/glucose ratio without changes in lactate or pyruvate is unspecific and does not support energetic impairment or hyperglycolysis [5,7].Finally, despite using different insulin starting points, we observed a synchronic effect starting 3 hours after insulin onset in an analysis of high temporal resolution. This is a strong indicator that the decrease in brain glucose was not just a delayed reaction to the hemorrhage but was in some way related to insulin treatment. The biochemical processes behind this reaction, however, remain to be elucidated.
Competing interests
The authors declare that they have no competing interests.
Authors: G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: I Cranston; P Marsden; K Matyka; M Evans; J Lomas; P Sonksen; M Maisey; S A Amiel Journal: J Cereb Blood Flow Metab Date: 1998-02 Impact factor: 6.200
Authors: Paul M Vespa; David McArthur; Kristine O'Phelan; Thomas Glenn; Maria Etchepare; Daniel Kelly; Marvin Bergsneider; Neil A Martin; David A Hovda Journal: J Cereb Blood Flow Metab Date: 2003-07 Impact factor: 6.200
Authors: Ulrich W Thomale; Martin Griebenow; Angelika Mautes; Thomas F Beyer; Nils-Kristian Dohse; Ralf Stroop; Oliver W Sakowitz; Andreas W Unterberg; John F Stover Journal: Neurol Res Date: 2007-09 Impact factor: 2.448